Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 1216-1223, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (87)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Allard, W. J.
Right arrow Articles by Yeung, K. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Allard, W. J.
Right arrow Articles by Yeung, K. K.
Related Collections
Right arrow Proteomics and Protein Markers
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 1998;44:1216-1223.)
© 1998 American Association for Clinical Chemistry, Inc.

Enzymes and Protein Markers

Novel immunoassay for the measurement of complexed prostate-specific antigen in serum

W. Jeffrey Allarda, Zeqi Zhou, and Kwok K. Yeung

a Author for correspondence. Fax 914-524-2195; e-mail jeffrey.allard.b{at}bayer.com.

Serum prostate-specific antigen (PSA) is an effective diagnostic tool for detection of prostate cancer (CaP) at an early and potentially curable stage, but specificity is low. Studies have shown that the proportion of serum PSA complexed with {alpha}-1-antichymotrypsin (ACT) is higher in men with CaP than in men with benign prostate disease. We developed a novel immunoassay for complexed PSA based on the unique binding properties of a monoclonal antibody that fails to bind free PSA in the presence of antibodies specific for free PSA. The assay measured mixtures of free and complexed PSA accurately, and the measured values of free + complexed PSA in artificial mixtures and in patient sera were equivalent to the measured value of total PSA. Both the serum concentration and the proportion of complexed PSA was substantially higher in patients with CaP compared with patients with benign prostate disease. The cPSA assay may have utility in improving specificity in screening for prostate cancer.




The following articles in journals at HighWire Press have cited this article:


Home page
 JCOHome page
H. Lilja, D. Ulmert, T. Bjork, C. Becker, A. M. Serio, J.-A. Nilsson, P.-A. Abrahamsson, A. J. Vickers, and G. Berglund
Long-Term Prediction of Prostate Cancer Up to 25 Years Before Diagnosis of Prostate Cancer Using Prostate Kallikreins Measured at Age 44 to 50 Years
J. Clin. Oncol., February 1, 2007; 25(4): 431 - 436.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
D. Ulmert, C. Becker, J.-A. Nilsson, T. Piironen, T. Bjork, J. Hugosson, G. Berglund, and H. Lilja
Reproducibility and Accuracy of Measurements of Free and Total Prostate-Specific Antigen in Serum vs Plasma after Long-Term Storage at -20 {degrees}C
Clin. Chem., February 1, 2006; 52(2): 235 - 239.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
T. Keller, H. Butz, M. Lein, M. Kwiatkowski, A. Semjonow, H.-J. Luboldt, P. Hammerer, C. Stephan, and K. Jung
Discordance Analysis Characteristics as a New Method to Compare the Diagnostic Accuracy of Tests: Example of Complexed Versus Total Prostate-Specific Antigen
Clin. Chem., March 1, 2005; 51(3): 532 - 539.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
S Jain, A G Bhojwani, and J K Mellon
Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers
Postgrad. Med. J., November 1, 2002; 78(925): 646 - 650.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Martinez, F. Espana, M. Royo, J. M. Alapont, S. Navarro, A. Estelles, J. Aznar, C. D. Vera, and J. F. Jimenez-Cruz
The Proportion of Prostate-specific Antigen (PSA) Complexed to {alpha}1-Antichymotrypsin Improves the Discrimination between Prostate Cancer and Benign Prostatic Hyperplasia in Men with a Total PSA of 10 to 30 {micro}g/L
Clin. Chem., August 1, 2002; 48(8): 1251 - 1256.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. Stephan, K. Jung, M. Lein, P. Sinha, D. Schnorr, and S. A. Loening
Molecular Forms of Prostate-specific Antigen and Human Kallikrein 2 as Promising Tools for Early Diagnosis of Prostate Cancer
Cancer Epidemiol. Biomarkers Prev., November 1, 2000; 9(11): 1133 - 1147.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
K. Jung, B. Brux, M. Lein, B. Rudolph, G. Kristiansen, S. Hauptmann, D. Schnorr, S. A. Loening, and P. Sinha
Molecular Forms of Prostate-specific Antigen in Malignant and Benign Prostatic Tissue: Biochemical and Diagnostic Implications
Clin. Chem., January 1, 2000; 46(1): 47 - 54.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
K. Jung, U. Elgeti, M. Lein, B. Brux, P. Sinha, B. Rudolph, S. Hauptmann, D. Schnorr, and S. A. Loening
Ratio of Free or Complexed Prostate-specific Antigen (PSA) to Total PSA: Which Ratio Improves Differentiation between Benign Prostatic Hyperplasia and Prostate Cancer?
Clin. Chem., January 1, 2000; 46(1): 55 - 62.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
B. L. Croal, I. Mitchell, A. Dickie, P. A. Duff, N. P. Cohen, I. S. Ross, K. Jung, B. Brux, P. Sinha, M. Lein, et al.
Complexed Prostate-specific Antigen and the ""Prostate-specific Antigen Gap"" • The authors of the Technical Brief cited above reply:
Clin. Chem., November 1, 1999; 45(11): 2040 - 2041.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
K. Jung, B. Brux, A. Knabich, M. Lein, P. Sinha, D. Schnorr, and S. A. Loening
A Gap Between Total Prostate-specific Antigen and the Sum of Free Prostate-specific Antigen Plus {alpha}1-Antichymotrypsin-Prostate-specific Antigen in Patients with Prostate Carcinoma but not in Those with Benign Prostate Hyperplasia
Clin. Chem., March 1, 1999; 45(3): 422 - 424.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.